Evaluation of FluoroType MTB for direct detection of Mycobacterium tuberculosis complex and GenoType MTBDRplus for determining rifampicin and isoniazid resistance

dc.contributor.authorGenç, Gonca Erköse
dc.contributor.authorSatana, Dilek
dc.contributor.authorYıldırım, Esra
dc.contributor.authorErturan, Zayre
dc.contributor.authorYeğenoğlu, Yıldız
dc.contributor.authorUzun, Meltem
dc.contributor.authorUzun, Meltem
dc.date.accessioned2019-08-31T12:10:23Z
dc.date.accessioned2019-08-13T09:37:37Z
dc.date.available2019-08-31T12:10:23Z
dc.date.available2019-08-13T09:37:37Z
dc.date.issued2018
dc.departmentMühendislik ve Doğa Bilimleri Fakültesi
dc.descriptionWOS: 000458741300024
dc.description.abstractIn recent years, several molecular methods have been introduced for diagnosis of Mycobacterium tuberculosis complex (MTBC), and detecting the drug resistance in clinical specimens. The FluoroType MTB (FT MTB) assay uses real-time polymerase chain reaction (PCR) to detect MTBC in clinical specimens. GenoType MTBDRplus is a line probe assay which detects MTBC, as well as rifampicin, and isoniazid resistance. In this study, the diagnostic performances of FT MTB and GenoType MTBDRplus were evaluated. In total, 247 specimens (124 respiratory, 123 non-respiratory) were analyzed comparing mycobacterial growth methods and FT MTB. GenoType MTBDRplus was used for the specimens positive for MTBC. In all, 23 (9.3%) of 247 specimens were positive for both the culture and FT MTB assay; therefore, the GenoType MTBDRplus assay was performed on 23 clinical specimens. The results were concordant with the drug susceptibility test results. The FT MTB assay provided quick and reliable direct detection of MTBC from the clinical specimens with high sensitivity (95.8%) and specificity (100%). Although the performance of GenoType MTBDRplus was problematic in clinical specimens with mycobacterial levels below the detection limits of the assay, it was a reliable test for cultivated specimens.
dc.identifier.doi10.1080/13102818.2018.1466662
dc.identifier.endpage1004
dc.identifier.issn1310-2818
dc.identifier.issn1314-3530
dc.identifier.issue4
dc.identifier.scopusqualityQ3
dc.identifier.startpage999
dc.identifier.urihttp://dx.doi.org/10.1080/13102818.2018.1466662
dc.identifier.urihttps://hdl.handle.net/20.500.12436/971
dc.identifier.volume32
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorYıldırım, Esra
dc.language.isoen
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofBiotechnology & Biotechnological Equipment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDrug resistance
dc.subjectDrug susceptibility testing
dc.subjectIsoniazid
dc.subjectRifampicin
dc.subjectMycobacteria
dc.subjectMycobacterium tuberculosis complex
dc.titleEvaluation of FluoroType MTB for direct detection of Mycobacterium tuberculosis complex and GenoType MTBDRplus for determining rifampicin and isoniazid resistance
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationb5a82952-4d72-40ce-a36d-095ee30803f8
relation.isAuthorOfPublication.latestForDiscoveryb5a82952-4d72-40ce-a36d-095ee30803f8

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Erkose-Genc-2018-Evaluation-of-fluorotype-mtb-for-di.pdf
Boyut:
779.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale dosyası / Article file